ReviewPharmaceuticals (Basel, Switzerland)2018
Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation.
Review in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Navigating Regulatory Frameworks and Compliances for Bacteriophages as Therapeutic Agents.Current pharmaceutical biotechnology · 2026Review
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- Resensitisation of Methicillin-ResistantPharmaceutics · 2023Article
- Engineering of the CHAPk Staphylococcal Phage Endolysin to Enhance Antibacterial Activity against Stationary-Phase Cells.Antibiotics (Basel, Switzerland) · 2021Article
- The Synergistic Effect of Biosynthesized Silver Nanoparticles and Phage ZCSE2 as a Novel Approach to Combat Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.International journal of molecular sciences · 2020Review
- Article
- Bacteriophages and the One Health Approach to Combat Multidrug Resistance: Is This the Way?Antibiotics (Basel, Switzerland) · 2020Review
- The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence.PHAGE (New Rochelle, N.Y.) · 2020Article
- Pharmacological limitations of phage therapy.Upsala journal of medical sciences · 2019Review
- Bacteriophages in Natural and Artificial Environments.Pathogens (Basel, Switzerland) · 2019Review
- Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.Frontiers in microbiology · 2019Review
- Antibiotic Therapy Using Phage Depolymerases: Robustness Across a Range of Conditions.Viruses · 2018Article
- Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resurgence of research into phage biology and therapy is, in part, due to the increasing need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern Europe and initial success within the food industry, commercialized phage products have yet to enter other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations to establish an infection which produces enough progeny phages to reduce the bacterial population in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics. In the current article the biological limitations of whole phage-based therapeutics and their derived antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to address these issues, in the context of medical and non-medical applications, will also be included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.